Brett Kaplan, M.D., Joins as Chief Financial Officer
Emily Minkow Promoted to Chief Business Officer
NEW YORK–(BUSINESS WIRE)– Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing
gene therapies for patients with Parkinson’s disease and other
neurodegenerative and lysosomal disorders, today announced the
appointment of Brett Kaplan, M.D., to Chief Financial Officer. In
addition, Emily Minkow was promoted to Chief Business Officer from her
former role as Executive Vice President of Business Development and
Strategy. Dr. Kaplan joins Ms. Minkow and Prevail’s existing executive
team: Franz Hefti, Ph.D., Chief Development Officer; Jeffrey Sevigny,
M.D., Chief Medical Officer; and Founder and CEO Asa Abeliovich, M.D.,
“With our programs moving forward for patients with unmet needs in
neurodegenerative and lysosomal disorders, our executive team brings the
broad experience crucial to the future success of our mission,” said Asa
Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail.
“We are very pleased to welcome Brett to Prevail and congratulate Emily
on her well-deserved promotion to Chief Business Officer. Brett, Emily,
Franz and Jeff bring robust track records in drug development, including
specific expertise in neurodegenerative diseases.”
Prior to Prevail, Dr. Kaplan was a Managing Director at Evercore, where
he spent eight years concentrating on biopharma M&A and equity
financings. Prior to Evercore, he was an Equity Research Analyst at
Cowen, where he covered large cap pharmaceuticals. Earlier in his
career, Dr. Kaplan held senior positions at Cubist and Lilly focused on
corporate and business development. He holds an MBBCh and an MBA from
the University of Witwatersrand in South Africa.
Prior to Prevail, Ms. Minkow held positions of increasing responsibility
at Celgene Corporation for seven years, most recently as Executive
Director of Business Development. There, she led deal evaluation and
execution across a broad range of licensing transactions, collaborations
and M&A. Ms. Minkow also held roles at Celgene in marketing and business
operations. Earlier in her career, Ms. Minkow was a consultant for
Frankel Group. She holds an MBA from Harvard Business School and a
Bachelor’s degree from Princeton University.
Dr. Hefti brings more than 15 years of experience in early-stage
neurology companies. Prior to Prevail, he was Chief Operations Officer
at Proclara Biosciences, President and Chief Executive Officer of Acumen
Pharmaceuticals, Chief Scientific Officer at Avid Radiopharmaceuticals,
and Executive Vice President of Drug Development at Rinat Neuroscience.
Earlier in his career, Dr. Hefti was Senior Vice President of
Neuroscience Research at Merck & Co. and Head of Neuroscience Research
at Genentech. He also held positions in academia at the University of
Miami and the University of Southern California. Dr. Hefti holds a Ph.D.
from the University of Zurich and completed his postdoctoral research at
the Massachusetts Institute of Technology.
Dr. Sevigny brings more than 15 years of clinical research, executive
leadership and technical expertise across the development spectrum for
multiple neurological diseases. He joins Prevail from Roche, where he
was Vice President and Global Head of Translational Medicine
Neuroscience. Prior to Roche, he was Senior Director of Clinical
Development at Biogen, where he led the development of the Company’s
early and late stage neurodegeneration portfolio. Previously, he held
positions at Novartis AG and Merck & Co., and held academic appointments
at Albert Einstein School of Medicine and Columbia University College of
Physicians and Surgeons. Dr. Sevigny holds an M.D. from Tufts University
School of Medicine and an A.B. in biochemistry from Bowdoin College.
ABOUT PREVAIL THERAPEUTICS
Prevail Therapeutics is a biotechnology company focused on developing
novel gene therapies for patients with Parkinson’s disease and other
neurodegenerative and lysosomal disorders. Prevail was founded by Dr.
Abeliovich in 2017, together with The Silverstein Foundation for
Parkinson’s with GBA, REGENXBIO and OrbiMed, and is headquartered in New
Source: Prevail Therapeutics, Inc.